Safety and efficacy of targeting PP2A in ovarian clear cell carcinoma using Dostarlimab and LB-100

Find more information here

If you or someone you know is battling cancer, discover how Dostarlimab can be an effective treatment option

Contact us

To learn more about the clinical trial, including eligiblity requirments and participating centers, please visit clinicaltrials.gov and enter ID NCT06065462